Table 1.
Baseline Characteristics of Enrolled Patients.
| Male:Female | 7:22 | |
| Age (years) | 50.4 ± 15.9 | |
| <50 | 15 (51.7 %) | |
| 50- 65 | 8 (27.6 %) | |
| ≥65 | 6 (20.7 %) | |
| Risk factor scores for fracture* | 5.7 ± 2.8 | |
| Past history of fracture | 5 (17.2 %) | |
| fracture site | all lumbar spine | |
| fracture fragility | all | |
| Number of postmenopausal patients | 9 (31.0 %) | |
| Underlying disease (n) | ||
| systemic lupus erythematosus | 16 (55.2 %) | |
| rheumatoid arthritis | 6 (20.7 %) | |
| dermetomyoisitis/polymyositis | 2 (6.9 %) | |
| Behçet disease | 1 (3.4 %) | |
| Sjögren syndrome | 1 (3.4 %) | |
| renal diseases | 3 (10.4 %) | |
| Disease duration (years) | 17.4 ± 9.3 | |
| Initial GC dose (mg/day) | 147.2 ± 235.6 | |
| Current GC dose (mg/day) | 7.4 ± 5.4 | |
| <5 | 6 (20.7 %) | |
| 5- 7.5 | 10 (34.5 %) | |
| ≥7.5 | 13 (44.8 %) | |
| GC duration (years) | 17.4 ± 9.3 | |
| Pre-denosumab treatment | ||
| Bisphosphonate | 18 (62.1 %) | |
| Vitamin D | 20 (69.0 %) | |
| Vitamin K | 2 (6.9 %) | |
| Fracture risk factor score | 6.4 ± 2.2 | |
| BMD, YAM (%) | ||
| Lumbar spine | 91.5 ± 23.9 | |
| <70 | 2 (6.9 %) | |
| 70- 80 | 10 (34.5 %) | |
| ≥80 | 17 (58.6 %) | |
| Femoral neck | 86.4 ± 22.2 | |
| <70 | 4 (13.8 %) | |
| 70-80 | 5 (17.2 %) | |
| ≥80 | 20 (29.0 %) | |
| Bone turnover markers | ||
| serum NTX (nmol BCE/L) | 19.2 ± 10.6 | |
| serum BAP (U/L) | 12.1 ± 6.5 |
Data are the mean ± standard deviation.
*Scores for the categories of each fracture predictor [4].
Prior fragility fractures: No = 0, Yes = 7
Age (years): <50 = 0, 50- 65 = 2, ≥65 = 4
GC dose (PSL equivalent mg/day): <5 = 0, 5-7.5 = 1, ≥7.5 = 4
Lumbar BMD (%YAM): ≥80 = 0, 70-80 = 2, <70 = 4
BAP: bone-specific alkaline phosphatase, BMD: bone mineral density, GC: glucocorticoid, NTX: N-terminal cross-linked telopeptide of type 1 collagen, PSL: prednisolone, YAM: young adult mean